Inflammation

, Volume 20, Issue 1, pp 43–56 | Cite as

Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-Lys(L18) in rat macrophage cultures and dog synovial fluid

  • Tadaki Sugawara
  • Sanae Takada
  • Megumi Miyamoto
  • Mamoru Nomura
  • Michiyuki Kato
Original Articles

Abstract

To examine the involvement of cytokines in the mechanisms of N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine, MDP-Lys(L18)-induced arthritis, we analyzed interleukin-1 (IL-1), tumor necrosis factor (TNF), colony-stimulating factor (CSF), and neutrophil chemotactic factor (NCF) by bioassays in the rat macrophage-conditioned medium (Mø-CM) stimulated by MDP-Lys(L18) in vitro and the synovial fluid from dogs treated subcutaneously with MDP-Lys(L18) for 14 days in vivo. The dog showed arthritis characterized by swelling of the knee joint, increased synovial fluid and thickened synovial membrane, and a single subcutaneous injection of MDP-Lys(L18) was previously shown to induced synovitis in rat tarsal joint. IL-1, TNF, CSF, and NCF activities in Mø-CM were increased by MDP-Lys(L18), while only NCF activity was detected in the dog synovial fluid. Partial purification procedures revealed that NCF in Mø-CM was not leukotriene B4 but a protein having heparin-affinity, and, in addition, immuno-reactive IL-8 was evident to be in Mø-CM. The NCF activity in the dog synovial fluid was not inhibited by dialysis, showing that NCF is a protein substance, possibly a chemokine. These results suggest that MDP-Lys(L18) produces a chemokine, such as IL-8, which recruits neutrophils to the synovial membrane for subsequent development of synovitis in rats and dogs.

Keywords

Arthritis Tumor Necrosis Factor Synovial Fluid Knee Joint Subcutaneous Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ellouz, F., A. Adam, R. Ciorbaru, andE. Lederer. 1974. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.Biochem. Biophys. Res. Commun. 59:1317–1325.Google Scholar
  2. 2.
    Nakajima, R., Y. Ishida, F. Yamaguchi, T. Otani, Y. Ono, M. Nomura, T. Une, andY. Osada. 1988. Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice.Arzneim. -Forsch./Drug Res. 38(II):986–992.Google Scholar
  3. 3.
    Tsubura, E., T. Nomura, H. Niitani, S. Osamura, T. Okawa, M. Tanaka, K. Ota, H. Nishikawa, T. Masaoka, M. Fukuoka, A. Horiuchi, K. Furuse, M. Ito, K. Nagai, T. Ogura, M. Kozuru, N. Hara, K. Hara, M. Ichimaru, andK. Takatsuki. 1988. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.Arzneim. -Forsch. I Drug Res. 38(II):1070–1074.Google Scholar
  4. 4.
    Sugawara, T., M. Kato, andS. Takayama. 1992. Arthritis and hematological changes induced by an analogue of muramyl dipeptide in rats.Fund. Appl. Toxicol. 18:395–404.Google Scholar
  5. 5.
    Ono, Y., T. Iwasaki, M. Sekiguchi, andT. Onodera. 1988. Subacute toxicity of muroctasin in mice and dogs.Arzneim.-Forsch./Drug Res. 38(II):1024–1027.Google Scholar
  6. 6.
    Sugawara, T., S. Takada, K. Furuhama, S. Takayama, M. Nomura, andM. Kato. 1995. Different effect of cyclosporin A on arthritides induced by a muramyl dipeptide analogue or the complete adjuvant in rats.Int. J. Exp. Path. 76:191–199.Google Scholar
  7. 7.
    Akasaki, M., H. Masayasu, W. Tsukada, andT. Takegoshi, 1988. Specific binding sites of muroctasin on murine macrophages.Arzneim.-Forsch./Drug Res. 38(II):978–980.Google Scholar
  8. 8.
    Azuma, I., andT. Otani. 1994. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans.Med. Res. Rev. 14:401–414.Google Scholar
  9. 9.
    Arend, W. P., andJ.-M. Dayer. 1990. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.Arthritis Rheum. 33:305–315.Google Scholar
  10. 10.
    Brennan, F. M. 1994. Role of cytokines in experimental arthritis.Clin. Exp. Immunol. 97:1–3.Google Scholar
  11. 11.
    Ohuchi, K., M. Watanabe, K. Yoshizawa, S. Tsurufuji, H. Fujiki, M. Suganuma, T. Sugimura, andL. Levine. 1985. Stimulation of prostaglandin E2 production by 12-O-tetradecanoylphorbol 13-acetate (TPA)-type and non-TPA-type tumor promoters in macrophages and its inhibition by cycloheximide.Biochem. Biophys. Acta 834:42–47.Google Scholar
  12. 12.
    Iscove, N. N., J. S. Senn, J. E. Till, andE. A. McCulloch. 1971. Colony formation by normal and leukemic human marrow cells in culture: Effect of conditioned medium from human leukocytes.Blood 37:1–5.Google Scholar
  13. 13.
    Sugawara, T., M. Miyamoto, S. Takayama, andM. Kato. 1995. Separation of neutrophils from blood in human and laboratory animals and comparison of the chemotaxis.J. Pharmacol. Toxicol. Method 33:91–100.Google Scholar
  14. 14.
    Akasaki, M. T. Takashi, Y. Kita, andW. Tsukada. 1987. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18).Agent Action 22:144–150.Google Scholar
  15. 15.
    Shimoda, K., S. Okamura, N. Harada, F. Omori, andY. Niho. 1990. Production of interleukin-6 from macrophages by MDP-Lys(L18), romurtide.Res. Commun. Chem. Pathol. Pharmacol. 70:289–296.Google Scholar
  16. 16.
    Nakajima, R., Y. Ishida, K. Akahane, M. Sekiguchi, andY. Osada. 1991. Stimulatory effect of romurtide on hematopoiesis in monkeys.Arzneim.-Forsch./Drug Res. 41(I):60–65.Google Scholar
  17. 17.
    Shimoda, K., S. Okamura, C. Kawasaki, F. Omori, T. Matsuguchi, andY. Niho. 1990. Muroctasin [MDP-Lys(L18)] augments the production of granulocyte colony-stimulating factor (G-CSF) from human peripheral blood mononuclear cellsin vitro.Int. J. Immunopharmac. 12:729–735.Google Scholar
  18. 18.
    Akahane, K., F. Yamaguchi, Y. Kita, T. Une, andY. Osada. 1990. Stimulation of macrophages by muroctasin to produce colony-stimulating factors.Arzneim.-Forsch./Drug Res. 40(I):179–183.Google Scholar
  19. 19.
    Fontana, A., H. Hengartner, E. Weber, K. Fehr, P. J. Grob, andG. Cohen. 1982. Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis.Rheumatol. Int. 2:49–53.Google Scholar
  20. 20.
    Westacott, C. I., J. T. Whicher, I. C. Barnes, D. Thompson, A. J. Swan, andP. A. Dieppe. 1990. Synovial fluid concentration of five different cytokines in rheumatic diseases.Ann. Rheum. Dis. 49:676–681.Google Scholar
  21. 21.
    Yocum, D. E., L. Esparza, S. Dubry, J. B. Benjamin, R. Volz, andP. Scuderi. 1989. Characteristics of tumor necrosis factor production in rheumatoid arthritis.Cell. Immunol. 122:131–145.Google Scholar
  22. 22.
    Hopkins, S. J., andA. Meager. 1988. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.Clin. Exp. Immunol. 73:88–92.Google Scholar
  23. 23.
    Williamson, D. J., C. G. Begley, M. A. Vadas, andD. Metcalf. 1988. The detection and initial characterization of colony-stimulating factors in synovial fluid.Clin. Exp. Immunol. 72:67–73.Google Scholar
  24. 24.
    Xu, W. D., G. S. Firestein, R. Taetle, K. Kaushansky, andN. J. Zvaifler. 1989. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions.J. Clin. Invest. 83:876–882.Google Scholar
  25. 25.
    Saklatvala, J., S. J. Sarsfield, andY. Townsend. 1985. Pig interleukin 1: Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever.J. Exp. Med. 162:1208–1222.Google Scholar
  26. 26.
    Dayer, J.-M., B. Beutler, andA. Cerami. 1985. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.J. Exp. Med. 162:2163–2168.Google Scholar
  27. 27.
    Gowen, M., D. D. Wood, E. J. Ihrie, M. K. B. McGuiRE, andR. G. G. Russell. 1983. An interleukin 1 like factor stimulates bone resorptionin vitro.Nature 306:378–380.Google Scholar
  28. 28.
    Thomson, B. M., G. R. Mundy, andT. J. Chambers. 1987. Tumor necrosis factorsα andβ induce osteoblastic cells to stimulate osteoclastic bone resorption.J. Immunol. 138:775–779.Google Scholar
  29. 29.
    Pettipher, E. R., G. A. Higgs, andB. Henderson. 1986. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint.Proc. Natl. Acad. Sci. U.S.A. 83:8749–8753.Google Scholar
  30. 30.
    Henderson, B., andE. R. Pettipher. 1989. Arthritogenic actions of recombinant IL-1 and tumour necrosis factorα in the rabbit: Evidence for synergistic interactions between cytokinesin vivo.Clin. Exp. Immunol. 75:306–310.Google Scholar
  31. 31.
    van de Loo, A. A. J., O. J. Arntz, andW. B. van den Berg. 1992. Flare-up of experimental arthritis in mice with murine recombinant IL-1.Clin. Exp. Immunol. 87:196–202.Google Scholar
  32. 32.
    Stimpson, S. A., F. G. Dalldorf, I. G. Otterness, andJ. H. Schwab. 1988. Exacerbation of arthritis by IL-1 in rat joints previously injured by peptidoglycan-polysaccharide.J. Immunol. 140:2964–2969.Google Scholar
  33. 33.
    Hom, J. T., A. M. Bendele, andD. G. Carlson. 1988. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice.J. Immunol. 141:834–841.Google Scholar
  34. 34.
    Killar, L. M., andC. J. Dunn. 1989. Interleukin-1 potentiates the development of collageninduced arthritis in mice.Clin. Science 76:535–538.Google Scholar
  35. 35.
    Cooper, W. O., R. A. Fava, C. A. Gates, M. A., Cremer, andA. S. Townes. 1992. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta.Clin. Exp. Immunol. 89:244–250.Google Scholar
  36. 36.
    Kato, Y., J. Ikegami, M. Yamamoto, M. Moriwaki, N. Shigemoto, T. Ishito, T. Naganuma, Y. Mataki, T. Hara, andT. Deguchi. 1991. Repeated dose toxicity of marograstgim (KW-2228): Subcutaneous administration to rats for 13 weeks.Oyo Yakuri/Pharmacometrics (Jpn) 41:499–537.Google Scholar
  37. 37.
    Arend, W. P. 1993. Interleukin-1 receptor antagonist.Adv. Immunol. 54:167–227.Google Scholar
  38. 38.
    Symons, J. A., J. A. Eastgate, andG. W. Duff. 1990. A soluble binding protein specific for interleukin 1β is produced by activated mononuclear cells.Cytokine 2:190–198.Google Scholar
  39. 39.
    Barrera, P., A. M. T. Boerbooms, E. M. Janssen, R. W. Sauerwein, H. Gallati, J. Mulder, T. de Boo, P. N. M. Demacker, L. B. A. van de Putte, andJ. W. M. van der Meer. 1993. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factorα, and interleukin-6 levels in rheumatoid arthritis: Longitudinal evaluation during methotrexate and azathioprine therapy.Arthritis Rheum. 36:1070–1079.Google Scholar
  40. 40.
    Arend, W. P., andJ.-M. Dayer. 1995. Inhibition of the production and effects of interleukin-1 and tumor necrosis factorα in rheumatoid arthritis.Arthritis Rheum. 38:151–160.Google Scholar
  41. 41.
    Ford-Hutchinson, A. W., M. A. Bray, M. V. Doig, M. E. Shipley, andM. J. H. Smith. 1980. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.Nature 286:264–265.Google Scholar
  42. 42.
    Oppenheim, J. J., C. O. C. Zachariae, N. Mukaida, andK. Matsushima. 1991. Properties of the novel proinflammatory supergene “intercrine” cytokine family.Ann. Rev. Immunol. 9:617–648.Google Scholar
  43. 43.
    Watanabe, K., S. Kinoshita, andH. Nakagawa. 1989. Purification and characterization of cytokine-induced neutrophil chemoattractant produced by epithelioid cell line of normal rat kidney (NRK-52E cell).Biochem. Biophys. Res. Commun. 161:1093–1099.Google Scholar
  44. 44.
    Brennan, F. M., C. O. C. Zachariae, D. Chantry, C. G. Larsen, M. Turner, R. N. Maini, K. Matsushima, andM. Feldmann. 1990. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells.Eur. J. Immunol. 20:2141–2144.Google Scholar
  45. 45.
    Koch, A. E., S. L. Kunkel, J. C. Burrows, H. L. Evanoff, G. K. Haines, R. M. Pope, andR. M. Strieter. 1991. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8.J. Immunol. 147:2187–2195.Google Scholar
  46. 46.
    Forrest, M. J., G. J. Eiermann, R. Meurer, L. A. Walakovits, andD. E. MacIntyre. 1992. The role of CD18 in IL-8 induced dermal and synovial inflammation.Br. J. Pharmacol. 106:287–294.Google Scholar
  47. 47.
    Endo, H., T. Akahoshi, A. Nishimura, M. Toneoawa, K. Takagishi, S. Kashiwazaki, K. Mastushima, andH. Kondo. 1994. Experimental arthritis induced by continuous infusion of IL-8 into rabbit knee joints.Clin. Exp. Immunol. 96:31–35.Google Scholar
  48. 48.
    Peveri, P., A. Walz, B. Dewald, andM. Baggiolini. 1988. A novel neutrophil-activating factor produced by human mononuclear phagocytes.J. Exp. Med. 167:1547–1559.Google Scholar
  49. 49.
    Djeu, J. Y., K. Matsushima, J. J. Oppenheim, K. Shiotsuki, andD. K. Blanchard. 1990. Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8.J. Immunol. 144:2205–2210.Google Scholar
  50. 50.
    Schröder, J.-M., N. L. M. Persoon, andE. Christophers. 1990. Lipopolysaccharide-stimulated human monocytes secrete, apart from neutrophil-activating peptide 1/interleukin 8, a second neutrophil-activating protein. NH2-terminal amino acid sequence identity with melanoma growth stimulatory activity.J. Exp. Med. 171:1091–1100.Google Scholar
  51. 51.
    Wolpe, S. D., andA. Cerami. 1989. Macrophage inflammatory proteins 1 and 2: Members of a novel superfamily of cytokines.FASEB J. 3:2565–2573.Google Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Tadaki Sugawara
    • 1
  • Sanae Takada
    • 1
  • Megumi Miyamoto
    • 1
  • Mamoru Nomura
    • 1
  • Michiyuki Kato
    • 1
  1. 1.Drug Safety Research Center, Development Research LaboratoriesDaiichi Pharmaceutical Co., Ltd.TokyoJapan

Personalised recommendations